Immunai

Immunai is developing AI-powered solutions to revolutionize the discovery and development of immunotherapies. The company's platform integrates single-cell multiomics, machine learning, and big data computing to map the immune system at scale. Immunai's insights are used to identify and validate novel therapeutic targets and to develop new immunotherapies that are more effective and less toxic than existing treatments. Immunai's pipeline includes programs in a variety of therapeutic areas, including cancer, infectious diseases, and autoimmune diseases. The company's lead product candidate, IMI-101, is a small molecule inhibitor of a key checkpoint molecule that is involved in the suppression of the immune system. IMI-101 is currently in Phase 1 clinical trials for the treatment of advanced solid tumors.